Pfizer Neurontin Class Improperly Denied, Court Says

Pfizer Inc. may have to face lawsuits by insurers alleging the company improperly marketed the epilepsy drug Neurontin after an appeals court found the cases were improperly denied class-action status.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.